clinical trial · NCT07175220
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Jiangsu HengRui Medicine Co., Ltd.·phase2·recruiting·n = 200
Locally Advanced or Metastatic Non-small Cell Lung CancerSHR2554; SHR-A2102SHR2554; AdabelimumabSHR2554; SHR-1701
brief summary
Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
started
Oct 9, 2025
primary completion
Oct 1, 2028
completion
Oct 1, 2028
last updated
Nov 18, 2025
official title
A Multicenter, Open Label Phase II Clinical Study on the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination With Other Anti-tumor Treatments in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol